Twelve months after infection with COVID-19+, the patients’ END-1 (p = 0.002), END-2 (p = 0.012), END-3 (p = 0.029), GSTpi (p = 0.008) concentrations, and GR activity (p = 0.043) decreased compared to the levels observed during the acute phase of the disease (Figure 5 and Figure 6). The gene discussed is GSR; the disease is COVID-19.